On this page, you’ll find information on how bamlanivimab is being distributed across the country and how to identify infusion sites of care in your state. Be sure to scroll down to our Access FAQs which also provide more information regarding the process to order product and reimbursement.
The federal government, in conjunction with state health departments, will allocate supply of bamlanivimab to individual sites of care across the United States proportionally based on confirmed COVID-19 cases. Sites that have been allocated product will be contacted by and can agree to accept shipments from AmerisourceBergen, a distributor. If you are a healthcare provider and have questions about whether or not your site of care has been allocated product, you may contact your state health department directly. A list of state health departments can be found here. If you cannot get ahold of your state health department, or have additional questions, please call our dedicated Lilly COVID Hotline at 1-855-545-5921.
If you have a question about enrolling a patient in a clinical trial, please visit our Lilly Trial Guide.
Find an infusion site near you
Some states are partnering with the National Infusion Center Association (NICA) to make it easier to identify infusion site locations by state. Click "Go" to be redirected to the COVID infusion therapy search tool, hosted by NICA.* Please note that not all states are included and a site’s inclusion in this tool does not imply current availability of doses.Go
Frequently Asked Questions
FAQs regarding access to bamlanivimab
Clinical investigators, hospitals or clinical sites interested in participating in one of Lilly’s clinical trials for a potential COVID-19 treatment should call 1-877-CT-LILLY (1-877-285-4559) or email email@example.com
Ensuring the authenticity of bamlanivimab
Eli Lilly and Company is committed to patient safety and ensuring that people have accurate information about investigational bamlanivimab, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate bamlanivimab to protect patients from products that might be dangerous and lead to serious and life-threatening harm.
If you believe you have purchased or have been offered counterfeit bamlanivimab, please report it to the FDA.